FN1 and neoplasm: Considering the tumor-promoting roles of Fn on the various aspects of CRC development, current drugs targeting Fn have only been used to treat Fn-associated inflammation, it is unknown whether drugs targeting Fn, particularly those with fewer side effects, can induce CRC regression alone or in combinatory treatment with first-line treatment of advanced CRC.